TheEdgeResearch
Home / Stocks / AUPH

Aurinia Pharmaceuticals Inc. (AUPH)

NASDAQ Healthcare Biotechnology
$14.70 ▼ -1.28%
Market Cap
$1.97B
Sector
Healthcare
Industry
Biotechnology
Beta
1.41
52-Wk Range
13.52-19.25
CEO
Kevin C. Tang
Country
CA
Currency
USD

Aurinia Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Edmonton, AB, CA. The stock last traded at $14.70, down 1.28% on the session, giving a market capitalisation of $1.97B. On trailing twelve-month figures it carries a trailing P/E of 6.20, a net margin of 97.7%. Its beta of 1.41 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
6.20
Price / Sales
6.12
Price / Book
2.98
EV / EBITDA
10.12
Gross margin
90.7%
Operating margin
48.6%
Net margin
97.7%
Return on equity
—
Debt / equity
0.09
Current ratio
6.12
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
128
IPO date
2014-09-03
Headquarters
Edmonton, AB, CA
About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Comparable companies

Aurinia Pharmaceuticals Inc. is most often compared with the following Healthcare names:

ACRSALMSATTOBHVNELDNEVMNMLTXTRAXVERA
More research on AUPH
AUPH technical analysis AUPH TheEdge Score Compare against peers
Open full interactive analysis & DCF →